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Molecular basis of Tousled-Like Kinase 2 activation
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Tousled-like kinases (TLKs) are required for genome stability and normal development in
numerous organisms and have been implicated in breast cancer and intellectual disability. In
humans, the similar TLK1 and TLK2 interact with each other and TLK activity enhances ASF1
histone binding and is inhibited by the DNA damage response, although the molecular
mechanisms of TLK regulation remain unclear. Here we describe the crystal structure of the
TLK2 kinase domain. We show that the coiled-coil domains mediate dimerization and are
essential for activation through ordered autophosphorylation that promotes higher order
oligomers that locally increase TLK2 activity. We show that TLK2 mutations involved in
intellectual disability impair kinase activity, and the docking of several small-molecule inhi-
bitors of TLK activity suggest that the crystal structure will be useful for guiding the rationale
design of new inhibition strategies. Together our results provide insights into the structure
and molecular regulation of the TLKs.
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The plasticity of chromatin structure is critical for the reg-ulation of essential cellular processes required for normaldevelopment and aging, including DNA replication,
DNA repair, cell division and transcription1,2. The major subunit
of chromatin is the nucleosome, a stretch of DNA wrapped
around a histone core octamer3. Histones are regulated at the
transcriptional level and through myriad post-translational
modiﬁcations (PTMs) that occur both in complexes with his-
tone chaperones and in the context of the nucleosome4. Histone
chaperones, including ASF1, CAF-1, and HIRA, are required for
the dynamic maintenance of chromatin structure and play diverse
roles in the regulation of histone PTMs, subcellular localization,
storage and deposition4.
Anti-silencing factors 1a and 1b (ASF1a and ASF1b) are his-
tone H3–H4 chaperones that mediate replication-dependent and
-independent pathways of histone exchange5,6. In conjunction
with other factors, ASF1 enforces transcriptional silencing, facil-
itates transcription through heterochromatic regions and sup-
ports promoter maintenance7–9. ASF1 regulates histone usage
during DNA replication by promoting the incorporation of par-
ental and newly synthesized histones, as well as buffering histone
pools upon replication stress or arrest4,10,11. The loss of ASF1
leads to global transcriptional deregulation, DNA replication
defects, and results in an activated DNA damage response (DDR),
gross chromosomal rearrangements and DNA damage sensitivity
to a wide variety of lesions12–16.
The precise mechanisms by which ASF1 is regulated remain
unclear, but ASF1 was identiﬁed as a target of the Tousled kinase
(TSL) and Tousled-like kinases (TLKs) that can inﬂuence its
stability and histone binding capacity17–19. TLKs belong to a
distinct branch of Ser/Thr kinases, that appear to be constitutively
expressed in most cell lines and tissues, and they exhibit the
highest levels of activity during S-phase19–21. An essential role in
proper ﬂower and leaf development was described for TSL22,
whereas its homologues in human, mouse, Drosophila melano-
gaster, Caenorhabditis elegans and Trypanosoma brucei, have
been implicated in DNA repair, DNA replication, transcription
and mitosis18,20,23–26. In mammals, there are two distinct TLK
genes, TLK1 and TLK2. TLK activity is rapidly attenuated by the
activation of the DDR, and in the case of TLK1, this is due to the
direct phosphorylation of a C-terminal residue by Checkpoint
kinase 1 (CHK1)25,27. In addition to ASF1, TLK1 has been
reported to phosphorylate RAD9, a component of the
RAD9–RAD1–HUS1 (9-1-1) complex that regulates CHK1 acti-
vation28–31, indicating complex coordination between TLK
activity and the checkpoint response. Recent work has linked
TLK2 activity to DNA damage checkpoint recovery32 and shown
that TLK1 and TLK2 play largely redundant roles in genome
maintenance26. This is consistent with the fact that they form
heterocomplexes, as suggested by previous work19,33.
At the organismal level, the single Tlk gene in C. elegans and
Drosophila is essential for viability23,24. Tlk1-deﬁcient mice are
also viable, while mice lacking Tlk2 perish during embryogenesis
due to placental failure26. Bypass of the placenta using a condi-
tional allele allowed the generation of adult Tlk2 null animals
that, like Tlk1-deﬁcient mice, showed no overt phenotypes. Copy
number ampliﬁcations and increased expression of TLK2 have
been recently reported in ER-positive breast cancer34–37 and
TLK2 mutations have been implicated in intellectual disability
(ID) patients38 suggesting that TLK activity inﬂuences human
disease.
Here, we report a detailed molecular characterization of the
crystal structure of the kinase domain of TLK2 in complex with
ATPγS, thus providing insight into its structural properties and
mode of activation. Our biochemical analysis has identiﬁed key
autophosphorylation sites critical for its activity and indicates that
TLK2 is activated through a cis-autophosphorylation mechanism.
Moreover, we examined the effect of TLK2 mutations reported in
ID patients in a structural context and determined how they
impair TLK2 activity.
Results
Architecture and activity of human TLK2. Human TLK1 and
TLK2 polypeptides are composed of an N-terminal region, a
middle region of helices predicted to contain three coiled coils
(CC) and a C-terminal kinase domain that shows 94% identity
between TLK1 and TLK2 (Fig. 1a, Supplementary Figure 1). The
C-terminal regions of the kinase domains contain many possible
phosphorylation sites in their carboxy terminus (C-tail), one of
which, S743, has been reported to negatively regulate activity in
TLK118,25,27. The ﬁrst 200 amino acids of the N-terminus are
predominantly disordered and are predicted to contain a nuclear
localization signal (NLS). The CC domains of Arabidopsis TSL,
which contain an additional insertion in the ﬁrst CC, have been
reported to mediate oligomerization and activity33. Sequence
alignment from plants to mammals showed that both the kinase
and the predicted CC domains are highly conserved (Supple-
mentary Figure 1) and the last residues of the C-tail were pre-
dicted to be unstructured. Based on these sequence alignments
and secondary structure predictions, we generated a series of
constructs with N- and C-terminal deletions to facilitate the
expression and analysis of the different sections of the TLK2
protein (Fig. 1a, Supplementary Figure 2). These human TLK2
variants were overexpressed in Escherichia coli in the presence or
absence of lambda phosphatase in order to generate phosphory-
lated and unphosphorylated proteins (Supplementary Figure 2
and Methods). Similarly, we also generated versions of the kinase
domain with and without the C-tail; KdomL and KdomS. Finally,
a catalytically inactive version (kinase dead (KD)) of the con-
structs was produced by generating the D613A mutation in the
catalytic loop (Supplementary Figure 2).
The oligomerization of TLKs has been suggested based on
indirect experiments but has not been examined biochemically to
date33. To determine the oligomerization status of the puriﬁed
proteins, we performed size exclusion chromatography coupled to
a Multiple Angle Laser Light Scattering (MALLS) instrument.
The kinase domain constructs behaved as monomers in solution
(≈37 kDa) and an increase in hydrodynamic radius was observed
in the samples that were not co-expressed with the lambda
phosphatase, demonstrating that phosphorylation (indicated as
–p) results in a conformational change (Fig. 1b). In contrast, the
longer ΔN-TLK2 and ΔN-TLK2s proteins showed a molecular
weight consistent with the dimeric form of the kinase (≈137 kDa),
providing clear biochemical evidence that TLKs can form dimers
and that this is dependent on the region containing the CC
domains (Fig. 1c). We have not detected dissociation and
interconversion of monomers in the isolated ΔN-TLK2 or ΔN-
TLK2s over a time span of several days. While ΔN-TLK2 and
ΔN-TLK2s formed perfect dimers when co-expressed with
lambda phosphatase, the phosphorylated forms exhibited larger
hydrodynamic radii indicating the presence of additional
oligomeric species, especially in the case of ΔN-TLK2 containing
the C-tail (Fig. 1c).
As previous work had linked the dimerization ability of TSL to
its catalytic activity33, we expressed a series of Strep-FLAG (SF)-
tagged TLK2 alleles with mutations in the N-terminus, CC
domains or kinase domain in human cells and examined
protein–protein interactions and kinase activity in pull-downs
with streptavidin (Strep). In Strep pull-downs of tagged wild-type
(WT) TLK2, we readily observed co-precipitation of TLK1, ASF1,
a key TLK substrate, and LC8, another prominent interactor that
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does not appear to be a target of TLK2 activity (Fig. 1d)26. All of
these interactions were maintained in the N-terminal deletion
(ΔN2-TLK2) mutant lacking the ﬁrst 161 residues, as well as the
KD protein. To address the potential roles of the CC domains, we
generated deletion mutants lacking each of the three domains.
Deletion of CC1 strongly impaired the interaction with both
TLK1 and LC8 but did not appear to inﬂuence that of ASF1. In
contrast, neither the CC2 nor CC3 domain had a clear inﬂuence
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on any of the protein–protein interactions (Fig. 1d). We next
examined kinase activity in the pull-downs using Myelin basic
protein (MBP), a commonly used kinase substrate surrogate. The
effect of the TLK2-KD mutation was clearly evident, as
autophosphorylation and substrate phosphorylation were reduced
to background levels compared to TLK2-WT (Fig. 1e). The
deletion of the N-terminus resulted in highly elevated autopho-
sphorylation and substrate phosphorylation, suggesting that it
may play a negative regulatory role and that it is not required for
activity. Deletion of any of the individual CC domains did not
abolish TLK2 activity, indicating that none of these domains, or
the heterodimerization with TLK1, are required for TLK2 activity.
We next examined the subcellular localization of these mutants
and found that with the exception of the ΔN-TLK2 mutant that
contains the putative NLS, all of the mutants showed nuclear
localization (Fig. 1f). Therefore, we concluded that TLK2 is a
predominantly nuclear protein whose dimerization requires the
predicted CC1 domain, and the phosphorylation of the enzyme
promotes the assembly of higher order oligomers, likely involving
both the CC domains and the C-tail.
TLK2 auto- and trans-phosphorylation. Our method to generate
the recombinant TLK2 proteins permits the isolation of samples
in the presence or absence of autophosphorylations, allowing the
study of how these PTMs affect the catalytic properties of the
enzyme. A kinase assay was used to measure auto and substrate
phosphorylation of the different puriﬁed proteins. We ﬁrst
examined the autophosphorylation rates of our various TLK2
constructs over a 7-min time course that was triggered by the
addition of ATP (Fig. 2a, Supplementary Figure 3). The unpho-
sphorylated ΔN-TLK2 and ΔN-TLK2s proteins showed a con-
tinuous increase in the levels of autophosphorylation over the
time course of the experiment, in contrast to their respective
phosphorylated forms ΔN-TLK2-p and ΔN-TLK2s-p. Notably,
the presence of the C-tail dramatically enhanced autopho-
sphorylation in the presence of the CC domains in the ΔN-TLK2
protein, probably by providing a region rich in phosphorylatable
residues that could be involved in kinase regulation. The levels of
autophosphorylation of the kinase domain species, KdomS and
KdomL, were negligible in comparison to the ΔN-term forms,
suggesting that dimerization enhances the activity of the enzyme
(Fig. 2b). Moreover, these results show that TLK2 can be activated
without the need of an external triggering kinase, as is the case for
CDKs, as well as many other kinases39. To address whether the
autophosphorylation reaction is uni- or bimolecular, we used a
competition assay, incorporating different ratios of a ΔN-TLK2-
KD mutant (D613A). These experiments revealed a reduction in
autophosphorylation intensity with increasing amounts of ΔN-
TLK2-KD (Fig. 2c), suggesting that TLK2 autophosphorylation
follows a unimolecular process and that autophosphorylation
occurs in the context of the protein dimer.
While over 100 potential TLK substrates have been proposed40,
only a few have been validated or examined in any functional
detail. These include ASF1, a histone H3-H4 chaperone, and
RAD9, a member of the 9-1-1 complex that plays an important
role in the DDR17,18,29–31. To test substrate phosphorylation by
the various TLK2 constructs, we used the generic kinase substrate
MBP and bacterially expressed ASF1a and monitored phosphor-
ylation in a reaction triggered with radiolabelled ATP. Consistent
with the autophosphorylation data, the Kdom variants were much
less active in catalysing phosphate transfer to MBP compared to
the ΔN-TLK2 constructs (Fig. 2d, Supplementary Figure 4). An
increase in activity on MBP was observed in all of the
phosphorylated variants when compared to their respective
unphosphorylated forms. Minor differences were observed in
the activity of the phosphorylated variants due to the presence or
absence of the C-tail, which appeared to decrease activity in the
context of the ΔN-TLK2 proteins, consistent with its proposed
negative regulatory role in TLK1 (Fig. 2d)25,27.
However, when the reaction was carried out with the speciﬁc
substrate ASF1a, no activity was observed with the Kdom
variants, suggesting that ASF1a recognition is dependent on the
CC domains (Fig. 2e, Supplementary Figure 4) and that ASF1a is
phosphorylated only by variants of TLK2 that are capable of
oligomerization. It is also notable that while the phosphorylated
ΔN-term TLK2 forms were much more active than the unpho-
sphorylated forms on MBP, less of a difference was seen when
ASF1a was used as a substrate. In the absence of the C-tail,
proteins exhibited similar activity, regardless of whether they
were co-expressed with lambda phosphatase, while in the
presence of the C-tail, phosphorylation had an inhibitory effect
(see Fig. 2e). These data suggested that TLK2 activity is more
regulated in the case of the physiological substrate ASF1a.
Mapping of TLK2 phosphosites. Our experiments showed that
all the variants were active when expressed in E. coli, suggesting
that TLK2 does not need the action of exogenous kinases for
activation. In addition, our biochemical characterization indi-
cated that the monomeric kinase domain, although active, dis-
played a negligible catalytic activity compared to the dimeric form
of the enzyme (Fig. 2b), which contains the CC region. Moreover,
phosphorylated forms of the dimer displayed higher orders of
oligomerization, while the kinase domain constructs remained
monomeric. To understand the mechanism of TLK2 activation,
we sought to identify the phosphorylation sites of TLK2 in our
controlled system expressing the protein in E. coli. Using mass
spectrometry (MS), we obtained full peptide coverage of the ΔN-
TLK2 construct produced in the presence or absence of lambda
phosphatase and the ΔN-TLK2-KD mutant. New phosphoryla-
tion sites were observed in our samples, especially in the 191–450
region around the CC domains (Fig. 3a–c, Supplementary
Data 1). To determine if these phosphosites were also detected in
Fig. 1 Architecture and characterization of TLK2. a TLK2 domain architecture and constructs used in this study. For a complete list see Supplementary
Figure 2. b Size exclusion chromatography (SEC) coupled with Multi-Angle Laser Light Scattering (MALLS) proﬁles were used to assess the
oligomerization state of the phosphorylated and unphosphorylated constructs with or without the C-tail for the kinase domain and c ΔN-TLK2 constructs.
The effect of the catalytically inactive mutant ΔN-TLK-KD (D613A mutation) is also included. d The indicated TLK2 mutants were overexpressed in AD293
cells by transient transfection and pulled down from cell lysates using Streptavidin resin. Protein–protein interactions were analyzed by western blotting for
TLK2, TLK1, ASF1 and LC8 (right panel). Input levels are shown in the left panel including the Ponceau red-stained membrane showing similar total protein
levels. The KD in this experiment bears the D592V mutation instead of D613A. e Kinase assays were performed from Streptavidin pull-downs performed as
in d. Kinase complexes were incubated with either MBP or ASF1a in the presence of 32P-ATP and autophosphorylation (TLK2) and substrate
phosphorylation assessed in dried SDS-PAGE gels exposed to a phosphoimager. f Immunoﬂuorescence analysis of exogenous TLK2 in transiently
transfected AD293 cells. Localization of TLK2 and mutant forms was determined by staining with anti-FLAG antibodies and co-staining of nuclei with DAPI.
Cytoplasmic localization of the ΔN-TLK2 mutant conﬁrms the presence of the NLS in the N-terminus of the protein. The scale bar represents 10 μm in all
the pictures. Uncropped gels and blots are shown in Supplementary Figures 10–15
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mammalian cells and whether they were inﬂuenced by the pre-
dicted NLS in the N-terminal fragment (Fig. 1a), we produced
ΔN-TLK2 and the full-length WT TLK2 in HEK293 cells.
We could detect the phosphosites in the 1–191 protein
segment, which have been previously reported in PhosphoSite-
Plus. Minor differences were observed between ΔN-TLK2 and the
full-length protein expressed in mammalian cells (Fig. 3c,
Supplementary Data 1). The absence of some of the phosphosites
in ΔN-TLK2 expressed in HEK293 may be due to the presence of
Ser/Thr phosphatases in mammalian cells that could remove
them during the puriﬁcation. Another possibility is that the large
expression of ΔN-TLK2 in the prokaryotic system leads to
phosphorylation of secondary sites with lower or no functional
relevance, which are, therefore, not observed in mammalian cells.
The differences of phosphorylation in the presence and absence
of the 1–190 N-terminal fragment are scarce, suggesting that the
nuclear localization of the enzyme does not change dramatically
its phosphorylation pattern (Supplementary Figure 5a–c).
Therefore, ΔN-TLK2 expressed in E. coli displays a phospho-
site landscape in similar regions to ΔN-TLK2 expressed in
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Fig. 2 Catalytic activity depends on TLK2 autophosphorylation. a Autoradiograms of TLK2 autophosphorylation activity for the kinase domain and the ΔN-
TLK2 constructs after a 30-min or 14-h exposure, respectively (see Supplementary Figure 4a for SDS-PAGE and the initial velocity plots). b Quantiﬁcation
of the autophosphorylation assay showing that the kinase domain is not efﬁcient as the ΔN-TLK2 constructs. The unphosphorylated ΔN-TLK2 displays the
larger activity in autophosphorylation. Data points indicate the relative autophosphorylation normalized to the autophosphorylation activity of ΔN-TLK2
(mean ± s.d., n= 3 biological replicates). See Supplementary Figure 4 for the details of the autophosphorylation rates of KdomL-p and ΔN-TLK2-p. c The
autophosphorylation of ΔN-TLK2 is a unimolecular reaction. The increasing ratios of the ΔN-TLK2-KD inactive mutant diminished the activity of the kinase.
The data points indicate the relative autophosphorylation of the ΔN-TLK2/ΔN-TLK2-KD reactions normalized to the activity of point 1 (mean ± s.d., n= 3
biological replicates). d, e Phosphorylation of TLK2 substrates. The activity is represented in a histogram for MBP and ASF1a phosphorylation by various
TLK2 constructs. The data points indicate the relative substrate phosphorylation for the TLK2 constructs normalized to the TLK2 construct with the highest
activity (mean ± s.d., n= 3 biological replicates). See Supplementary Figure 4 for autoradiograms and SDS-PAGE for MBP and ASF1a phosphorylation
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HEK293 cells. We continued our biochemical analysis in the E.
coli isolated sample which provides a more controlled scenario for
our study.
Altogether, the homodimeric ΔN-TLK2 expressed in E. coli
displays 41 phosphosites out of 67 possible Ser/Thr sites (Fig. 3c),
15 of which were in the kinase domain and six of them mapped
onto the C-tail. The rest, except S330 in the predicted CC2, were
found in the loops between the predicted CC domains. The heat
map based on hierarchical clustering analysis and the volcano
plot display the distribution of phosphorylation sites on TLK2,
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which clearly differs between active TLK2 and the KD variant
(Fig. 3a, b).
To understand the role of phosphorylation in the activation
process within the TLK2 dimer, we co-expressed in E. coli, in the
absence of lambda phosphatase, differentially tagged constructs,
His-ΔN-TLK2 and Strep-LSL-ΔN-TLK2-KD, in order to isolate a
heterodimer where only one of the kinase domains was inactive
(Fig. 3d, Supplementary Figure 6a). The presence of different tags
and the absence of interconversion of the heterodimer (checked
by MALLS after puriﬁcation) allowed the MS analysis of the
phosphopeptides from each distinct monomer. We obtained full
coverage of both monomers (Supplementary Figure 6b–d and
Methods) and the heat maps of the phosphosites shows two clear
clusters between the homodimers and the heterodimers (Fig. 3a).
A clear overall difference can be observed in the shared
phosphosites and the intensity/levels of phosphorylation in the
protein samples. To analyze speciﬁc differences, a t-test was
performed and the corresponding volcano plots showed a
difference in the phosphopeptide sites between the ΔN-TLK2
and ΔN-TLK2-KD homodimers (Supplementary Figure 6b). In
addition, clear phosphorylation differences were also observed in
the ΔN-TLK2-KD monomer depending on whether it was in the
context of a heterodimer or a homodimer (Supplementary
Figure 6a), while little differences were observed between the
monomers of ΔN-TLK2 and ΔN-TLK2-KD in the context of the
heterodimer (Fig. 3a, Supplementary Figure 6d).
The unique phosphosites observed in either the heterodimer
active subunit or in the heterodimer KD subunit were mapped
onto the molecule to illustrate the distinct phosphorylation sites
on each monomer (Fig. 3d). As expected the heterodimer
contained fewer phosphorylations in comparison to the wild-
type homodimer, as only 5 and 8 unique sites were found in ΔN-
TLK2-KD and ΔN-TLK2 monomers, respectively (Fig. 3d). We
observed that the heterodimer showed unique sites between the
two monomers, in agreement with our competition experiment
(Fig. 2c). Therefore, in this heterodimeric sample, the phosphor-
ylations must arise from the active monomer. These unique
phosphosites can be categorized into two groups, a ﬁrst one
including the phosphosites in the ΔN-TLK2-KD resulting from
inter-molecular phosphorylation (trans), and a second group
arising from intra-molecular phosphorylation (cis) in the ΔN-
TLK2 (Fig. 3d). The active ΔN-TLK2 monomer of the
heterodimer undergoes cis phosphorylations (S617, S686, T695
and T700) in the kinase domain and (S223, T301, S376 and S393)
in the oligomerization domain (Fig. 3d). The trans-phosphoryla-
tions in the ΔN-TLK2-KD monomer occur only in the C-tail
(S763 and S771) and the oligomerization domain (S226, S307 and
T385). A comparison of these results revealed that the
heterodimer lacks 17 phosphosites that are present in the active
homodimer. This indicated that the activity of both kinase
domains in the dimer is needed to achieve full
autophosphorylation of the molecule and suggests that initial
phosphorylations by one of the kinase domains in the dimer
makes new sites available that would be subsequently targeted by
the second catalytic domain. Therefore, we hypothesize that
initial autophosphorylation between the monomers could trigger
conformational changes leading to the full activation of the
enzyme. One example of such a possible stepwise autopho-
sphorylation can be observed in the C-tail where S771 and S763
are due to trans-phosphorylations (Fig. 3d), while the other
phosphosites in the C-tail (Fig. 3c) could occur in cis after the
phosphorylation of these residues, as they do not appear in the
heterodimer (Fig. 3d). Whether the TLK2 dimer is parallel or
antiparallel cannot be determined at this stage. However, a large
number of the phosphosites in the CC region, which have been
also detected in the protein expressed in mammalian cells, seem
to arise from trans-phosphorylation, suggesting that the CC
region of a monomer could be located in the proximity of the
kinase domain of the other subunit of the dimer.
Structure of the TLK2 kinase domain. TLKs represent a unique
kinase family, deﬁned by divergent protein sequence, mainly in
the activation loop, that is located between the Polo and AGC
kinase families in the kinome41. The catalytic domain of the
protein kinases shares a common fold consisting of an N-terminal
and a C-terminal lobe42,43. Two hydrophobic interaction net-
works, termed 'R- (regulatory) and C- (catalytic) spines', cross the
two lobes (Supplementary Figure 7). These elements are essential
for catalysis and together with the central F-helix44,45 and
encompass the activation loop, the catalytic loop and the DFG
motif, which constitute the kinase core.
Here, we present the structure of the kinase domain of human
TLK2; the unphosphorylated TLK2 kinase domain was crystal-
lized in complex with ATPγS46, a slowly hydrolysable ATP
analogue, and the structure solved at 2.8 Å resolution (Fig. 4a,
data collection and reﬁnement statistics are shown in Table 1).
The divergent sequence conservation of the catalytic domain of
TLK2, when compared to other kinases, is reﬂected in its
structure. A BLAST search of protein homologues in the PDB and
a subsequent sequence alignment and structural superposition, as
implemented in ENDSCRIPT47, showed major structural differ-
ences. The sausage plot indicates low sequence identity and large
r.m.s. deviations in many regions of the kinase domain, especially
those involving key regulatory elements, such as the activation
loop (Fig. 4b, c, Supplementary Figures 7–8).
Our unphosphorylated ATPγS TLK2 structure is in a pre-
active conformation. Although the R-spine is in the correct
alignment to create a platform for an active conformation,
important hallmarks of the active state, such as the salt bridge
between the conserved lysine and glutamate in the β3 and αC
helix (K491 and E514 in TLK2) are not observed (Fig. 4c). The
main characteristic features of TLK2 are its unusual ATP-binding
Fig. 3 TLK2 undergoes both cis- and trans-phosphorylation in the dimer. a Hierarchical clustering analysis of the phosphorylation sites of the ΔN-TLK2
constructs expressed in E. coli displayed in a heat map. Log-transformed and row-normalized intensities of phosphosites are shown in triplicates for the
heterodimer kinase-dead subunit (HeteroKD), the heterodimer active subunit (Hetero), the active homodimer (ΔN-TLK2) and the kinase-dead homodimer
(ΔN-TLK2-KD). b Volcano plot validation showing the regulation and signiﬁcance of phosphosites between the ΔN-TLK2 homodimer and the kinase-dead
ΔN-TLK2-KD homodimer. Phosphosites are labelled in black (signiﬁcant), light orange (highly signiﬁcant) and red (most highly signiﬁcant). c All detected
phosphorylation sites mapped on the ΔN-TLK2 domain scheme. The drawing does not imply a parallel arrangement of the dimer. Sites cannot be assigned
to individual molecules of the dimer. Boxed phosphosites have been detected in both HEK293 and E. coli-expressed ΔN-TLK2, while unboxed sites were
only found in the E. coli-expressed ΔN-TLK2. Font colour represents signiﬁcance as shown in Fig. 3b for the E. coli-expressed ΔN-TLK2 (black, light orange
and red). The unboxed green sites represent phosphosites observed exclusively in the ΔN-TLK2 expressed in HEK293 cells. d Schematic representation
depicting the unique phosphorylation sites observed in the heterodimer ΔN-TLK2 active subunit and in the ΔN-TLK2-KD kinase-dead subunit. The
phosphorylation sites in T208, T213, S218, S226, S289, T300, S307, T357, T380, S761 and T762 were observed in both subunits of the heterodimer (see
Supplementary Data 1 and Fig. 6a–d for volcano plots displaying distributions of peptides when comparing the different constructs)
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Fig. 4 Crystal structure of TLK2 kinase domain. a Ribbon diagram of the TLK2 kinase domain structure in complex with ATPγS. The protein fold shows the
classical N- and C-lobes and the important regulatory features associated with the kinase domain. The singular activation loop of TLK2 can be fully traced
in the structure (see Table 1 for data collection and reﬁnement). b To correlate structural and sequence conservation, we generated a sausage plot,
showing a variable tube representation of the Cα trace after a PDB query for performed with ENDSCRIPT. For this drawing, homologous protein structures
(1291 PDB ﬁles) were superposed onto the TLK2 kinase domain structure with ProFit. The size of the tube is proportional to the mean r.m.s. deviation per
residue between Cα pairs. The white to red colour ramping is used to visualize sequence conservation. c A detailed view of the structure showing the
ATPγS, catalytic and activation loops, P+1 loop and the αF helix. The key regulatory residues such as the DFG loop, the HYD, E647 and K661 are depicted
in sticks. An omit map for the ATPγS molecule at 1.25 σ level is included in the ﬁgure
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motif, GxGxxS (position 469–474), also observed in CK2a and
Cdc7, instead of the canonical GxGxxG seen in other kinases42,
and a long activation segment. This element is well-deﬁned in the
structure, exhibiting a stable conformation (Fig. 4c). Within the
activation segment is the T-loop, which is located in the C-
terminal part of the extended activation segment, and whose
phosphorylation is considered a critical regulatory element in
protein kinases48. Although there are some exceptions, such as
CaMK-II, many kinases contain a His–Arg–Asp (HRD or RD)
motif within the catalytic loop and the positive charge on the Arg
side chain serves to stabilize the phosphorylated activation loop
site49. However, TLK2 does not contain this motif, a Tyr residue
is located in the Arg position, suggesting that TLKs may not need
T-loop phosphorylation for activation (Fig. 4c, Supplementary
Figure 1).
All the phosphorylation sites detected in the kinase domain are
shown in stick representation (Fig. 5a). Out of the 15
phosphosites, we can locate nine of them in the structure of the
kinase domain, mainly in the C-lobe, around the catalytic and
activation loops. Unfortunately, we cannot observe the residues
phosphorylated in the C-tail (T750 to S771) because this region
was not included in our crystallized protein. Our experiments
suggest that cis autophosphorylation is likely to be responsible for
phosphorylating the S617, S686, T695 and S700 sites, while S474,
T483, S569, T640, and S666 could result from trans-
autophosphorylation within the dimer (Fig. 3e). Phosphorylations
in the P-loop have been observed to inﬂuence the regulation of
other kinases. The modelling of a phosphoserine instead of S474
in the P-loop of the kinase domain (Fig. 4a, Fig. 5a) suggests that
this modiﬁcation could affect nucleotide binding, leading to a
reduction in activity. There are few examples of P-loop
phosphorylation. One is found in Bcr–Abl, where pY272 impairs
binding to STI-571, resulting in a lack of response to the drug.
Additional examples are pS150 of the bacterial Ser/Thr kinase
HipA50 and pY15 of CDK251. Phosphorylation in these residues
has been shown to inhibit kinase activity by disturbing ATP
binding or by blocking the substrate-binding site, respectively.
The other observed phosphorylation in the TLK2 N-lobe, pT483,
could interact with the loop preceding the initial β-strand of the
N-lobe, rigidifying the connection to the CC3. This could
contribute to stabilizing the kinase domain and avoiding
ﬂexibility of this moiety. The rest of the phosphoresidues are
present in the C-lobe. pS569 is located near the C-spine and its
phosphorylation will likely aid in ﬁxing the conformation of the
catalytic loop through interactions with the main chain of A605
and C606. Its mutation to alanine would not allow this
interaction, but it could be favoured by hydrophobic contacts
with A605, thus not affecting the activity (Fig. 5a, b,
Supplementary Figure 9a, b). Although it has not been observed
in our mammalian expressed protein, an interesting phosphor-
ylation occurs in pS617, which is located just after the DFG motif.
A phospho-mimic mutation (Asp) of this residue inhibited the
kinase activity (Fig. 5a, b, Supplementary Figure 9a, b). This is
likely due to the fact that the presence of a phosphate will disturb
the F614 conformation, affecting the R-spine. A residue
conserved in both TLK1 and TLK2, T635, is in the position
analogous to the activating phosphorylation of CDK2 and this
residue was found phosphorylated in TLK1 (Anja Groth, personal
communication). However, as previously mentioned, TLK1 and
TLK2 do not contain an RD motif, suggesting that this would not
be required for activation. We have found only unphosphorylated
peptides containing this residue in our MS experiments both in E.
coli and HEK293. Therefore, its phosphorylation does not seem to
be essential for activity in vitro or likely to be the result of cis or
trans-autophosphorylation. The S635A and S635D mutations in
this residue reduced the activity of TLK2 but had converse effects
on overall autophosphorylation. While S635A showed somewhat
reduced autophosphorylation compared to TLK2-WT, it was
increased by the S635D mutation. This could indicate that S635 is
modiﬁed by another kinase in vivo to modulate TLK1/2 activity.
Near T635, pT640 could further stabilize the catalytic loop by
interacting with the main chain of the 590-HYD-592 motif,
holding an active catalytic loop conformation together with T640.
Interestingly, pT686 and pS695 seem to rigidify the loops
connecting the αG-helix most likely favouring the kinase activity
by stabilizing the P+1 loop region. The alanine mutations of
these two residues decrease the activity of the enzyme. Regarding
pS700, this residue is exposed to the solvent and is not clear how
its modiﬁcation could affect the kinase activity.
Intellectual disability mutations impair TLK2 activity. A recent
meta-analysis of data from over 2000 patients identiﬁed TLK2 as
one of ten new candidate genes for ID and other neurodevelop-
mental disorders38. These patients have de novo loss of function
mutations (DNM) and exhibit severe clinical features, such as
facial dysmorphisms. Two of the DNM mutations in TLK2 were
located on the N-lobe around the ATP-binding pocket, one was
found in the activation loop and the last one in the C-lobe
(Fig. 5c). Amino acids substituted on the kinase domain are
highlighted in sticks and surface representation to show the
Table 1 Crystal structure of TLK2 kinase domain, data
collection and reﬁnement statistics
Data collection TLK2 crystal, PDB: 5O0Y
Wavelength (Å) 1
Resolution range (Å) 72.76–2.86 (2.963–2.86)
Space group P 213
Unit cell (Å), ° a= b= c= 126.02; α= β= γ= 90
Total reﬂections 31,396 (3094)
Unique reﬂections 15,698 (1547)
Multiplicity 2.0 (2.0)
Completeness (%) 99.97 (100)
Mean I /sigma (I) 13.12 (0.54)
Wilson B-factor 97.07
R-merge 0.032 (1.29)
R-mean 0.045 (1.82)
CC1/2 0.999 (0.26)
CCa 1 (0.64)
Reﬁnement
Reﬂections used in reﬁnement 15,694 (1547)
Reﬂections used for R-free 790 (76)
R-work 0.20 (0.36)
R-free 0.22 (0.35)
Number of non-hydrogen atoms 2390
Macromolecules 2359
Ligands 31
Protein residues 288
RMS (bonds) (Å) 0.01
RMS (angles) ° 1.64
Ramachandran favoured (%) 93.1
Ramachandran allowed (%) 5.9
Ramachandran outliers (%) 1.0
Rotamer outliers (%) 3.8
Clashscore 2.5
Average B-factor 104.84
Macromolecules 86.33
Ligands 125.26
Number of TLS groups 1
Statistics for the highest-resolution shell are shown in parentheses
aFriedel mates were averaged when calculating reﬂection statistics
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04941-y ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2535 | DOI: 10.1038/s41467-018-04941-y | www.nature.com/naturecommunications 9
aS666
S617
S474
b
H493R
D629N
R720A
H518R
S569
T483
S686
T695
S700
T640
****
****
ns
*
****
****
****
***
ns
****
****
ns
ns
****
****
**
****
****
ns
K
in
as
e 
ac
tiv
ity
 (
a.
u.
)
TLK2 [auto-P]
MBP [substrate-P]
62
28
A
ut
o 
S
ub
st
ra
te
32P
W
T
H
49
3R
H
51
8R
H
51
8N
R
72
0A
W
T
D
62
9N
ΔN
-T
LK
2-
K
D
ΔN
-T
LK
2-
K
D
W
T
H
49
3R
H
51
8R
H
51
8N
R
72
0A
W
T
D
62
9N
ΔN
-T
LK
2-
K
D
ΔN
-T
LK
2-
K
D
2.5
2.0
1.5
1.0
0.5
0.0
C
on
tr
ol
T
LK
2
T
LK
2 
K
D
S
56
9A
S
61
7A
S
61
7D
S
68
6A
S
68
6D
S
65
9A
T
69
5A
S
74
8-
st
op
C
on
tr
ol
T
LK
2
T
LK
2 
K
D
S
56
9A
S
61
7A
S
61
7D
S
68
6A
S
68
6D
S
65
9A
T
69
5A
S
74
8-
st
op
MBP [5 μM]ASF1a [5 μM]
TLK2 LP [0.5 μM]
ASF1a
phosphorylation
MBP
phosphorylation
R
el
at
iv
e 
ki
na
se
 a
ct
iv
ity
R
el
at
iv
e 
ki
na
se
 a
ct
iv
ity
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
W
T
H4
93
R
H5
18
R
H5
18
N
R7
20
A
D6
29
N
ΔN
-T
LK
2-
KD
W
T
H4
93
R
H5
18
R
H5
18
N
R7
20
A
D6
29
N
ΔN
-T
LK
2-
KD
d
e
c
Fig. 5 Phosphorylation sites in the kinase domain. a Nine out of the 15 phosphorylation sites in the kinase domain can be modelled on the structure. The
sites are highlighted in stick and sphere representation and lie in the N-lobe, activation loop and C-lobe. The six phosphosites on the C-tail cannot be
observed because the crystallized construct lack that segment. b In vitro kinase assay of the indicated phosphorylation mutants of TLK2 isolated from
AD293 cells by Streptavidin pull-downs showing relative autophosphorylation and MBP phosphorylation (see Supplementary Figure 9a for the
autoradiograms and Supplementary Figure 9b IP pull-downs). The KD in this experiment bears the D592V mutation instead of the D613A. c Structure of
the kinase domain highlighting the position of the intellectual disorder and cancer mutants. The amino acids where mutations have been reported are
shown in stick–sphere representation. d In vitro kinase assay of the different ID and cancer mutants using MBP and ASF1a as substrates. e Quantiﬁcation
and comparison with the wild-type protein is represented in a histogram. The data points indicate the relative kinase activity of the TLK2-mutants
normalized to the activity of the wild-type protein (mean ± s.d., n= 3 biological replicates). See Supplementary Figure 9c–f for MBP and ASF1a
phosphorylation and autophosphorylation activities by the mutants
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location of these residues with respect to the activation segment
(Fig. 5c). Many of the substitutions are far away from the catalytic
loop. Nonetheless, we decided to investigate the activity of these
de novo mutations (H493R, H518R, D629N, R720A) by produ-
cing recombinant phosphorylated ΔN-TLK2-p mutants and
measuring their ability to phosphorylate MBP and ASF1a. Kinase
assays revealed H518R to be most severe, resulting in 85–90%
reduction of kinase activity (Fig. 5d, e). The H518R mutation is
located on the bottom of αC-helix and is conserved in other
kinases, constituting the RS3 of the regulatory spine44 (Supple-
mentary Figure 7). Mutations resulting in larger side chains, such
as an arginine, will disturb the organization of this key element
and therefore a decrease in its activity was expected. We gener-
ated a more conservative mutation, H518N. This protein showed
a 50% increase in activity on ASF1a compared to H518R, but
nonetheless, H518N was only 25% as active as the wild-type
protein, supporting our hypothesis (Fig. 5d). The H493R muta-
tion showed a 65% reduction in kinase activity compared to the
wild-type TLK2 (Fig. 5d, e, Supplementary Figure 9c, d). The side
chain of H493 also faces the ATP-binding pocket and is close to
the Glu–Lys salt bridge, so a bulkier side will affect the kinase
activity by distorting the catalytic side. While all of these mutants
are located in the N-lobe next to the catalytic site, the loss in
activity by R720A was the most surprising. This residue is located
on the penultimate helix (αH) with the side chain interacting with
D738. Therefore, its mutation to alanine will disrupt this inter-
action. One possibility is that the disruption of this interaction
could induce a reduction in activity by destabilizing the C-tail
positioning, thus impairing its autophosphorylation by the
enzyme. The larger decrease of kinase activity reduction observed
for the D629N mutation in the case of ASF1a in comparison with
MBP suggested that its effect could be related to speciﬁc substrate
recognition. This residue is not conserved in other kinases and is
exclusive to the TLKs that are deﬁned in part by their long and
divergent activation loop. We also compared the autopho-
sphorylation capability of these mutants with the wild-type pro-
tein (Supplementary Figure 9e, f). They showed a more than 50%
decrease in autophosphorylation, thus following a similar trend in
activity on ASF1a, supporting a mechanism by which autopho-
sphorylation triggers TLK2 to an active conformation for sub-
strate recognition and catalysis.
Docking of small-molecule inhibitors of TLK2 activity. The
implication of TLK2 in some types of cancer has suggested that
small-molecule inhibitors of its activity could be used as anti-
cancer agents36. While speciﬁc inhibitors of TLK2 have not yet
been identiﬁed, we tested several compounds previously identiﬁed
to have activity against TLK2 in a large screen of commercially
available small molecules52. Using immuno-precipitated protein
overexpressed in AD293 cells, we found that the non-speciﬁc
kinase inhibitors Staurosporine and Nocardiopsis completely
abolished TLK2 catalytic activity (Fig. 6a). We then tested several
inhibitors showing activity towards TLK2 that are known to
target CDK1 (CGP74541A) and GSK3 (Inhibitor XIII), as well as
the Indirubin derivatives E804 and indirubin-3′-monoxime
(Fig. 6a). Indirubin is an active component of Danggui Longhui
Wan, a traditional Chinese medicine formulation, whose
encouraging clinical results in chronic myelocytic leukaemia
patients have stimulated numerous studies on this compound53.
With the exception of the monoxime variant of indirubin, the
other three compounds substantially inhibited TLK2 kinase
activity (Fig. 6a). Using our structure, we performed an initial
analysis modelling the chemical compounds in our kinase
domain structure using HADDOCK54 in order to rationalize the
molecular bases of the observed inhibition (Fig. 6b, c). A future
in-depth study including more compounds will be needed to
evaluate possible inhibitors. In our study, the top 40 docking
solutions were selected for each compound and examined in
detail. Out of them, the best docking solutions without steric
clashes with the protein are shown (see Methods). In the case of
CGP74541, two solutions with minor differences were found,
while for indirubin E804, only one solution did not show clashes
with the protein. In the case of the GSK3 inhibitor XIII, four
different solutions could be docked by HADDOCK in the
nucleotide-binding pocket of the kinase domain. While these
compounds showed a substantial reduction in TLK2 activity, the
indirubin-3′-monoxime did not affect TLK2 activity. Structural
modelling indicated that this different behaviour could be due to
the absence of the aliphatic chain in 3′ and the presence of a
bulky iodine in the indol ring. The aliphatic region is engaged in
interactions in the cavity while the iodine atom will clash with the
protein moiety, thus avoiding binding and inhibition. These
preliminary results show that the structure of the kinase domain
of TLK2 can be successfully used in virtual screening for TLK2
inhibitors.
Discussion
TLKs have been implicated in key cellular processes ranging from
chromatin assembly to DNA replication, DNA repair and
transcription18,23,24,55,56. While genetic analyses in mice and cells
suggest largely redundant roles for TLK1 and TLK2 in develop-
ment and genome maintenance26, mutations speciﬁcally in TLK2
were identiﬁed in patients with neurological disorders and ID38,
potentially reﬂecting the critical role in placental development
that we recently reported, and speciﬁc functions have been pro-
posed for TLK1 and TLK232. In addition, frequent TLK2
ampliﬁcations were identiﬁed in oestrogen receptor (ER)-positive
luminal breast cancers and TLK2 inhibition, alone or in combi-
nation with tamoxifen, substantially inhibited the growth of
MCF7 xenograft tumours36. These data provide evidence for the
therapeutic value of TLK2 inhibition in breast cancers, where
ASF1b levels have been reported to also be elevated57, and
potentially other types of malignancies.
Although TLK activity has been shown to play an important
role in the regulation of chromatin assembly, and potentially
other processes, little mechanistic insight has been reported
regarding the regulation of its activity. Our structure–function
analysis of TLK2 reported here provides insights into the mole-
cular basis of its activation and provides a molecular context for
understanding this kinase family and the impact of mutations
that have been identiﬁed in ID patients. The structure of the
kinase domain will also facilitate the rational design of inhibitors
that may be valuable for the treatment of cancer progression and
the further interrogation of TLK function in model systems.
Our biochemical data indicate that the dimerization and fur-
ther oligomerization of TLK2 plays an important role in its
activation. TLK2 readily forms a dimer, and this dimeric
arrangement appears to be scaled-up in the form of higher order
oligomers following autophosphorylation (Fig. 2c), suggesting
that aside from triggering activation, further oligomerization will
increase the enzymatic activity by concentrating additional TLK2
molecules. TLK2 pull-downs show that it can associate with
TLK1 and that the CC1 is an essential region for that interaction
(Fig. 1d). Therefore, heterodimerization could be another reg-
ulatory layer in human TLKs, as it has been also observed in
receptor tyrosine kinases (RTKs)58.
Our activity assays show that the oligomeric arrangement of
the enzyme is also crucial for activity and substrate phosphor-
ylation. Autophosphorylation and therefore enzyme activation is
rapidly achieved in ΔN-TLK2, while almost negligible in the
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kinase domain constructs (Fig. 2a, b), which is in agreement
with the unimolecular behaviour of the autophosphorylation
reaction (Fig. 2c). Indeed, none of the phosphosites in the het-
erodimer containing a catalytically impaired kinase domain is
shared between the two monomers (Fig. 3d), supporting the
hypothesis that autophosphorylation occurs inside the
dimeric arrangement. Moreover, dimeric constructs are capable
of phosphorylating ASF1a while the kinase domains cannot,
indicating that the CC segment is involved in substrate recogni-
tion (Fig. 2d, e).
Our MS analysis showed that 41 out of 67 possible Ser/Thr
residues in ΔN-TLK2 expressed in E. coli are phosphorylated in
our assay. Twenty-six of these sites are located in the CC region,
mainly in the loops joining them, 15 are found in the kinase
domain, six of which lie in the C-tail (Fig. 3c). The presence of a
substantial fraction of these sites in the CC region has been also
observed when ΔN-TLK2 was expressed in HEK293 cells (Sup-
plementary Figure 3d, Supplementary Data 1) This represents the
ﬁrst identiﬁcation of functional autophosphorylation sites in
TLK2. Thus far, the majority of the phosphorylation sites
reported in public data are found in the N-terminal region and
the C-tail domain, that in TLK1 has been shown to be the site of
regulatory phosphorylation by CHK125,27,59. S563 in TLK1 that
corresponds to S569 in TLK2, which we identiﬁed speciﬁcally in
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Fig. 6 TLK2 inhibition and activation model. a In vitro kinase assay of TLK2 isolated from AD293 cells by Streptavidin pull-downs in the presence or
absence of the substrate MBP and the indicated kinase inhibitors. All inhibitors were used at 10 µM and the Coomassie stained gel shows equal loading of
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TLK2 activation
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04941-y
12 NATURE COMMUNICATIONS |  (2018) 9:2535 | DOI: 10.1038/s41467-018-04941-y | www.nature.com/naturecommunications
the context of the active homodimer, represents the only phos-
phorylation site in the kinase domain thus far reported59. In our
study, we found that 11 of the 25 new sites that we identiﬁed in
the CC region are conserved in TLK1. Many of them have also
been found when TLK2 and ΔN-TLK2 were expressed in
HEK293. While our data between bacteria and human cells are
largely consistent, we do not pretend that every site occurs under
physiological conditions. Here, we provide this information and
test four of them (Fig. 5b, Supplementary Figure 9), but they will
require further functional analysis in future work. In addition,
more than 20 phosphorylation sites have been reported in the N-
terminal domain of TLK2, suggesting that this is potentially an
important regulatory domain in vivo59. Compared to the wild-
type protein, we have observed consistently higher protein levels
of an N-terminal mutant expressed in cells and this protein shows
increased activity, suggesting a role in negative regulation
(Figs. 1d, e). Nevertheless, this observation does not seem to be
due to a difference in the phosphorylation in the absence of the
N-terminal fragment (Supplementary Figure 5a, b).
The analysis of the phosphorylation sites observed in the het-
erodimer showed a large decrease in the number of phosphor-
esidues, which also displayed an asymmetric distribution. This
suggests that a sequence of cis and trans-phosphorylations
between the monomers in different regions of the molecule may
occur to facilitate the activation of the enzyme. At least eight
phosphorylations appear in cis (S223, T301, S376, S393, S617,
S686, S695 and T700) while ﬁve are due to trans-phosphoryla-
tions (S226, S307, T385, S763 and S771). A detailed analysis of
the phosphosites in the kinase domain showed that pS763 and
pS771 in the C-tail, that have also been observed in HEK293
expressed TLK2, are generated by the active monomer suggesting
that these residues need to be trans-phosphorylated to allow the
subsequent cis- or trans-phosphorylation of the other four resi-
dues in the C-tail (S761, T762, S766 and S769) and the rest of the
kinase domain (Fig. 3e). Interestingly, a clear loss of phosphor-
ylation sites in the heterodimer was observed in the loops of the
CC region when compared with the homodimer (Fig. 3c, d). The
absence of these phosphosites in the heterodimer could reﬂect the
inability to fully activate the enzyme or be due to the fact that it
cannot assemble into higher order oligomers because of the lack
of phosphorylations in the C-tails. The absence of the C-tail in the
ΔN-TLK2-p inhibits the assembly of large oligomers (Fig. 2c)
indicating it is required to facilitate their formation.
Altogether, these data suggest a possible activation model
where the cis-autophosphorylations in the kinase domain (S686,
T695 and T700) would trigger a cascade of conformational
changes that would allow the trans- and cis-phosphorylation of
sites in the C-tail, as it has been described for members of the
closely related AGC kinase family60. Noteably, pS686 was also
detected in the HEK293 expressed proteins. The fact that the
monomeric kinase domains used in this study also displayed
catalytic activity, albeit signiﬁcantly reduced compared to ΔN-
TLK2, indicated that the cis-phosphorylations occur in the
monomeric kinase domain (Supplementary Data 1), but it cannot
reach full activation due to their monomeric status. The fully
activated TLK2 dimer would induce the formation of larger oli-
gomers where the phosphosites in the loops joining the CCs could
be further phosphorylated. The role of oligomerization in kinase
activation has been also postulated for RTKs58, IKKs61 or the
oncogenic fusion protein Bcr-Abl62. In this context, pT617, which
we have shown reduces the kinase activity, and pS474 could play
an important regulatory role in avoiding the phosphorylation of
inappropriate residues reducing the activity of the enzyme
(Fig. 6).
Our results contribute to the understanding of the molecular
mechanism by which the TLK family kinases are regulated and
provide important structural information that can facilitate the
future design of inhibitors for use in cancer therapy, as well as
information for the generation of phospho-speciﬁc antibodies to
track kinase activity in cells or tissues. Moreover, our data provide
insight into the consequences of the mutations observed in ID
patients and suggest that further investigation into the regulation
and dimeric structure of the TLKs is warranted.
Methods
Bacterial expression and puriﬁcation. For bacterial expression, TLK2 was cloned
into MCS1 of the pET-Duet1 vector with an N-terminal Hexa-His tag either by
restriction enzyme digest or In-Fusion cloning (Primer sequences and cloning
strategy are shown in Supplementary Table 1, 2). To generate the depho-
sphorylated forms of the proteins, the lambda protein phosphatase was cloned into
MCS2. Quickchange site-directed mutagenesis (Stratagene) was used to produce
the KD mutants. The generate the heterodimer, Strep2-LSL-TLK2L-D613A was
cloned into MCS2 of pETDuet containing His TLK2L in MCS1. All constructs were
veriﬁed by DNA sequencing.
All constructs were expressed in either E. coli NiCo21(DE3) (NEB) or Rosetta
(DE3) pLysS (Novagen, Millipore) at 37 °C. Expression was induced by the
addition of 0.3 mM isopropyl-β-D thiogalactopyranoside (IPTG) to a mid-log
culture, and then cells were harvested 3 h after induction. Recombinant proteins
were puriﬁed from clariﬁed crude cell extracts using a combination of immobilized
metal ion afﬁnity, anion exchange, Heparin and gel ﬁltration chromatography
(Puriﬁcation buffer compositions are shown in Supplementary Table 3). All the
TLK2-Kdom constructs were puriﬁed in two steps, NTA Ni-column
chromatography followed by size-exclusion chromatography (Superdex 200, GE
Healthcare). The longer forms of the protein required additional steps, either an
extra monoQ for the dephosphorylated forms or a monoQ and a heparin for the
phosphorylated forms, prior to SEC. Furthermore, unlike the dephosphorylated
proteins, the phosphorylated forms behaved differently and bound to the monoQ
column. SEC was performed in 20 mM Tris (pH 8), 150 mM NaCl and 0.25 mM
TCEP. The peaks containing TLK2 were concentrated, and aliquots of pure
proteins were ﬂash-frozen in liquid nitrogen and stored at −80 °C. Protein purity
was monitored by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and
electrospray ionization MS. The list of constructs used in this study is shown in
Supplementary Figure 2.
Protein structure determination and reﬁnement. Crystallization of the kinase
domain of TLK2 is described previously46. Brieﬂy, crystals were only obtained
when mixed with ATP-γ-S (2 mM) and appeared in two different screening con-
ditions: Natrix condition No. 1 (crystal type A; 20 mM HEPES pH 7, 2 M Li2SO4,
10 mM MgCl2) or Wizard II condition No. 37 (crystal type B; 1 M sodium/
potassium tartrate, 0.1 M Tris pH 7, 200 mM Li2SO4), at 277 K. Larger crystals were
reproduced in 24-well hanging-drop (Hampton Research Linbro plates) by mixing
1 µl protein and 1 µl reservoir solution. Crystals were mounted on CryoLoops
(Hampton Research) and ﬂash-cooled in liquid nitrogen. For data collection under
cryogenic conditions, crystals were brieﬂy soaked in a universal cryosolution,
consisting of mother liquor supplemented with 20% (w/v) glycerol. The structure
of the TLK2 kinase domain was determined by molecular replacement using
Balbes63. Native datasets were collected from single frozen crystals at 100 K using a
PILATUS detector at the PXI-XS06 beamline (SLS Villigen, Switzerland). Data
processing and scaling were accomplished with XDS64. The initial molecular
replacement solution was reﬁned using PHENIX65 and model building was per-
formed with Coot66. Data collection and reﬁnement statistics are summarized in
Table 1. The identiﬁcation and analysis of the hydrogen bonds and van der Waals
contacts was performed with the Protein Interfaces, Surfaces and Assemblies ser-
vice (PISA) and LIGPLOT at the European Bioinformatics Institute (http://www.
ebi.ac.uk/msdsrv/prot_int/pistart.html). Figures were generated using PyMOL.
Cloning of mammalian TLK2 constructs. All TLK2 constructs expressed in
mammalian cells for Fig. 1 were made in a pcDNA3.1 vector with an N-terminal
Strep-FLAG (SF) tag (a kind gift from C.J. Gloeckner)67. The wild-type TLK2
cDNA was introduced into the pcDNA3.1 plasmid generating the TLK2-WT
construct. The KD construct TLK2-KD, the phospho-site mutants or mimics
S569A, S617A, S617D, S635A, S635D, S686A, S686D, S659A, T695A and S474A
and the C-tail mutant S748stop were generated by QuickChange Lightning Site-
Directed Mutagenesis (Agilent Technologies). In order to generate domain-
deletion mutants, unique EcoRI and ScaI restriction sites were introduced as silent
mutations into the TLK2-WT plasmid using the QuickChange Lightning Site-
Directed Mutagenesis (Agilent Technologies). ΔN-TLK2 and TLK2-ΔCC3 were
generated using these sites to clone in PCR-ampliﬁed truncations. TLK2-ΔCC1 and
TLK2-ΔCC2 mutants were made by cloning PCR-ampliﬁed custom GeneArt
DNA-Strings (Thermo Fisher Scientiﬁc) into a pCR Blunt End II-TOPO vector
(Thermo Fisher Scientiﬁc) for storage, ampliﬁcation and sequencing. The resulting
insert was PCR ampliﬁed and cloned into the TLK2-WT plasmid to generate
TLK2-ΔCC1 and TLK2-ΔCC2 using the EcoRI and ScaI (NEB) sites. Digested
insert and plasmid were puriﬁed from agarose gels using the PureLink Quick Gel
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Extraction and PCR Puriﬁcation Combo Kit (Thermo Fisher Scientiﬁc) and ligated
using the Quick Ligation Kit (NEB) in a 3:1 ratio. All constructs were veriﬁed by
DNA sequencing (primer sequences are shown in Supplementary Tables 4, 5).
Transfections and pull-downs in mammalian cells. AD293 cells (Stratagene)
were grown in DMEM media (Thermo Fisher Scientiﬁc) supplemented with 10%
foetal bovine serum (FBS) (Sigma-Aldrich) and 50 U/ml penicillin/streptomycin
(Thermo Fisher Scientiﬁc) at 37 °C in a 5% CO2 incubator. Transient transfections
of 20 μg plasmid per 15 cm plate were carried out using polyethylenimine (PEI)
(Polysciences Inc.). Cells were harvested 48 h after transfection and collected by
scraping in PBS. Pellets were lysed in 1 ml lysis buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1% Tween-20, 0.5% NP-40, 1× protein inhibitor cocktail (Roche)
and 1× phosphatase inhibitor cocktails 2&3 (Sigma-Aldrich)) on ice for 20 min.
Cells were freeze-thawed three times or sonicated at medium intensity for 10 min,
and lysates were cleared by centrifugation at 16,000×g for 20 min at 4 °C. Proteins
were quantiﬁed using the DC Protein Assay (BioRad) and 100 µl was retained for
input; 2–4 mg of total protein extracts were incubated with 100 μl pre-washed
Strep-Tactin superﬂow resin (IBA GmbH) overnight at 4 °C using an overhead
tumbler. Resin was spun down (7000×g for 30 s) and transferred to Illustra
MicroSpin G-25 Columns (GE Healthcare). Resin was washed three times with
500 μl wash buffer (30 mM Tris, pH 7.4, 150 mM NaCl, 0.1% NP-40, 1× protein
inhibitor cocktail (Roche) and 1× phosphatase inhibitor cocktails 2&3 (Sigma-
Aldrich)). Proteins were eluted from the Strep-Tactin matrix with 50 μl of 5×
Desthiobiotin Elution buffer (IBA GmbH) in TBS buffer (30 mM Tris-HCl pH 7.4,
150 mM NaCl, 1× protein inhibitor cocktail (Roche) and 1× phosphatase inhibitor
cocktails 2&3 (Sigma-Aldrich)) for 10 min on ice.
Western blot and antibodies. For western blotting, 30 µg of input and 25 µl of
Strep-IP elute coming from AD293 cells were separated by SDS-PAGE and
transferred to Nitrocellulose membrane (GE Healthcare). Membranes were probed
with antibodies for FLAG (Sigma F3165, 1:1000), TLK1 (Cell Signaling 4125,
1:1000), ASF1 (Santa Cruz sc-53171, 1:800 or kindly provided by A. Groth, 1:2000),
and LC8 (Abcam ab51603, 1:1000). Primary antibodies were detected with
appropriate secondary antibodies conjugated to HRP and visualized by ECL-Plus
(GE Healthcare).
Pull-down kinase assays from cell lysates. In vitro kinase assays were performed
after Strep-IP puriﬁcation of N-SF-TLK2 mutants expressed in AD293 cells; 200 µg
of the Strep-IP eluate was used for the kinase reaction. Reactions were performed in
kinase assay buffer (50 mM Tris-HCl pH 7.5, 10 mMMgCl2, 2 mM DTT, 50 mg/ml
ATP) and 1× protein inhibitor cocktail (Roche) and 1× phosphatase inhibitor
cocktails 2&3 (Sigma-Aldrich), with 1 µg of substrate and 32P-γ-ATP. After
incubating for 30 min at 30 °C, the reaction was stopped by adding 2–3 µl of
Sample Buffer (6× SDS, 0.2% bromophenol blue and β-mercaptoethanol) and
boiled for 5 min. Samples were analyzed on SDS-PAGE, stained with Coomassie
Blue and dried for autoradiography. Substrates used for testing TLK2 mutants were
1 µg of MBP (Sigma-Aldrich) or 0.5 µg of GST-ASF1a (kindly provided by A.
Groth). Kinase inhibitors used in Fig. 6 were all
obtained from the InhibitorSelect 96-Well Protein Kinase inhibitor library II
(Merck).
Kinase assays with puriﬁed proteins. Standard kinase assay with substrates were
performed for 30 min at 30 °C in 10 μl of kinase buffer (10 mM Tris pH 7.5, 50 mM
KCl, 10 mM MgCl2, 1 mM DTT) supplemented with 50 μM cold ATP and 1.5μCi
[γ-32P] ATP (3000 Ci/mmol) and with 0–0.5 μM TLK2 proteins and 50 μM of the
substrate. Recombinant TLK2 proteins were obtained from over-expressions in E.
coli as described above. The substrates used for the kinase assays were: bovine
dephosphorylated MBP (Merck millipore, Catalogue #13–110), full-length human
Histone H3.1 (Sigma-Aldrich, SRP0177 Sigma) and full-length human ASF1a
puriﬁed as described above. The kinase reaction was stopped by the addition of
SDS sample buffer to be further separated by SDS polyacrylamide gel electro-
phoresis. Polyacrylamide gels were stained with the colloidal staining kit (Invi-
trogen) and further dried for 1 h 30 min at 80 °C. Radioactive TLK, MBP, Histone
H3.1 and ASF1a were identiﬁed by autoradiography; quantiﬁcation of the intensity
of the bands on the autoradiograms was achieved by densitometry using the Image
Studio Lite Software (LI-COR). Autophosphorylation assays were performed for 1
to 7 min (time course: 10 μl/min) at 30 °C in 80 μl and with 4 μM of the TLK
proteins. Sample preparation and quantiﬁcation of the obtained intensities is the
same as for the samples of the substrate kinase assays.
Immunoﬂuorescence imaging of TLK2 localization. AD293 cells were transiently
transfected with the indicated constructs and ﬁxed for 10 min in 4% paraf-
ormaldehyde at room temperature. Following blocking with 3% BSA/0.1% Triton
X-100 in PBS for 1 h, cells were stained with a mouse anti-FLAG antibody (1:500,
Sigma F1804) and the DNA stain DAPI (Sigma). Images were acquired with oil
immersion on a Zeiss LSM 780 confocal microscope at 40× magniﬁcation.
Size-exclusion chromatography–multi-angle light scattering. The oligomeric
state of TLK2 proteins, including the heterodimers, was analyzed by size-exclusion
chromatography coupled with multi-angle light scattering (SEC-MALS). Protein
samples were prepared at 1 mg/ml concentration and dialyzed into gel ﬁltration
running buffer, 20 mM Tris-HCl, 150 mM NaCl, 0.5 mM TCEP, pH 8.0. The
samples were loaded on a Superdex 200 Increase 10/300 size exclusion column (GE
Healthcare). The column outlet was directly connected to a DAWN HELEOS II
MALS detector (Wyatt Technology) followed by an Optilab T-rEX differential
refractometer (Wyatt Technology). Data were collected and analyzed using ASTRA
6 software (Wyatt Technology). Samples were run in triplicates. The monomeric
BSA was used as standard
(Sigma-Aldrich).
Expression of mammalian TLK2 for MS analysis. TLK2 full length and ΔN-
TLK2 were cloned into the HIS-TwinStrep N-term vector pCPR0197 (LIC-pTT5)
using Ligation Independent Cloning (LIC). The constructs were veriﬁed by colony
PCR followed by sequencing. The plasmids were transformed into Mach1-T1 cells
(Invitrogen) and 2.7 litres overnight cultures were GIGAprepped with the
Nucleobond PC 10000 EF kit (Macherey-Nagel). The constructs were boiled at 95 °
C for 5 min before transfection. The transfection was performed into Human
Embryonic Kidney EBNA 6E cell lines (HEK293 6E) grown in Freestyle 293 F17
expression medium (Invitrogen)+ 4 mM L-glu (Sigma). One day prior to trans-
fection, HEK293 6E cells were re-suspended in fresh Freestyle 293 F17 expression
medium+ 4 mM L-glu to a cell density of 1.2 × 106cells/ml and incubated at 37 °C
overnight. Approximately, 15 min before transfection, cells were re-suspended in
fresh unsupplemented Freestyle 293 F17 expression medium+ 4 mM L-glu at a cell
density of 20 × 106 cells/ml and incubated in the orbital shaker incubator at 37 °C,
70% humidity, 5% CO2 and 120 RPM (Ø50 mm), until being transfected. GIGA-
prep DNA of each construct (50 µg/ml ﬁnal) and Polyethylenimine “MAX” (PEI)
(polysciences) (100 µg/ml solution ﬁnal) were directly added to the cell suspension.
Complete Freestyle 293 F17 expression medium (1% FBS) was added to a ﬁnal
volume of 2 litres of cell suspension, 4 h post transfection. Three days post trans-
fection, the pellets were collected by centrifugation at 4000 RPM for 15 min at 4 °C.
The pellets were washed with PBS at 4 °C and stored at −20 °C. TLK2 proteins
were puriﬁed using Strep-tag/Strep-Tactin puriﬁcation system provided by IBA.
Prior to the puriﬁcation, the pellet was re-suspended in the appropriate lysis buffer.
The clear lysate was centrifuged at 15,000 RPM for 30 min at 4 °C and ﬁltered
(Minisart 0.22 µm ﬁlter). The fractions were loaded on a NuPAGE Bis-Tris gel to
check for protein integrity and purity.
Sample preparation for MS analysis. For MS-based analysis of TLK2 phos-
phorylation status, the protein was resolved by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), visualized by Coomassie staining
and in-gel trypsin digested (protocol adapted from Lundby and Olsen)68. Prior to
SDS-PAGE, proteins were reduced with 10 mM dithiothreitol (DTT) in 25 mM
ammonium bicarbonate (ABC) buffer for 45 min and alkylated with 55 mM
chloroacetamide (CAA) in 25 mM ABC solution for 30 min. SDS-PAGE was
performed with the different TLK2 constructs using 4–12% bis-tris gradient gels
(Invitrogen) and stained with the Colloidal Blue Kit (Invitrogen) according to
manufacturer instructions. For each sample, the TLK2-speciﬁc band was excised
from the gel in 1 × 2-mm cubes. Gel slices were destained with 50% ethanol in 25
mM ABC solution and dehydrated with 96% ethanol. Proteins were digested with
trypsin (modiﬁed sequencing grade, Sigma) overnight at 37 °C. Trypsin activity was
quenched by acidiﬁcation with triﬂuoroacetic acid (TFA), and peptides were
extracted from the gel pieces using increasing concentrations of acetonitrile.
Organic solvents were removed by evaporation in a SpeedVac centrifuge at 60 °C
and samples were desalted and concentrated by solid-phase extraction on reversed-
phased C18 STAGE tips.
Liquid chromatography–tandem MS. For all samples, peptides were eluted from
the C18 STAGE tips with 40% and 60% acetonitrile in 0.1% formic acid prior to
online nanoﬂow LC-MS/MS analysis. Samples were analyzed with a nanoscale
UHPLC system (EASY nLC1200, Thermo Fischer Scientiﬁc) connected to a Q
Exactive HF mass spectrometer (Thermo Fischer Scientiﬁc) through a nanoelec-
trospray ion source as previously described69. Brieﬂy, peptides were separated in a
15-cm analytical column (75-μm inner diameter) in-house packed with 1.9-μm
reversed-phase C18 beads (ReproSil-Pur AQ, Dr. Maisch) with a 76 min gradient
from 8 to 64% acetonitrile in 0.5% formic acid with a ﬂow of 250 nl/min. The mass
spectrometer was operated with spray voltage set to 2 kV, heated capillary tem-
perature at 275 °C and s-lens radio frequency level at 50%. Dynamic exclusion was
set to 30 s and all experiments acquired in positive polarity mode. Full scan
resolution was set to 120,000 at m/z 200, and the mass range was set to m/z
375–1500. Full scan ion target value was 3E6 with a maximum ﬁll time of 25 ms.
For every full scan, the 12 most intense ions were isolated and fragmented (nor-
malized collision energy 28%) by higher-energy collisional dissociation (HCD) with
fragment scan resolution of 30,000, and an ion target value of 1E5 with a maximum
ﬁll time of 45 ms.
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Processing and analysis of MS raw data. All raw LC-MS/MS data ﬁles were
analyzed using the MaxQuant software version 1.5.3.36 with the integrated
Andromeda search engine70,71. Data were searched against a target/decoy (forward
and reversed) version of the complete human UniProt database supplemented with
commonly observed contaminants and the sequences of the TLK2 constructs. In
addition, the ECOLI database was employed in the search to identify potential co-
purifying host cell proteins. Cysteine carbamidomethylation was searched as a ﬁxed
modiﬁcation. Protein N-terminal acetylation, oxidized methionine, pyroglutamate
formation from glutamine, and phosphorylation of serine, threonine and tyrosine
were searched as variable modiﬁcations. In addition, deamidation of asparagine
and glutamine was searched as an extra variable modiﬁcation. Phosphorylation site
localization probabilities and occupancies72 were determined by MaxQuant using
the PTM scoring algorithm70. An initial false discovery rate (FDR) of 1% and 5%,
respectively, was applied for peptide and phosphorylation site identiﬁcations.
Bioinformatic data analysis. Analysis of proteomics data was performed using the
Perseus software version 1.5.1.12 (http://www.coxdocs.org/). Only peptides with a
phosphorylation site localization probability of at least 0.75 (class I sites)73 were
included in the ﬁnal bioinformatics analyses. Phosphorylation site identiﬁcations
were ﬁltered for contaminants and reversed hits. Data were ﬁltered based on the
criteria that a phosphorylation site had to be identiﬁed in at least two replicates for
at least one of the sample groups in order to be included in the downstream
analysis. Data analysis was done using the raw intensity values, which were log2-
transformed and normalized by quantile-based normalization and median sub-
traction. Imputation from the lower end of the normal distribution was done to
replace missing values. A heat map was generated based on unsupervised hier-
archical clustering analysis using the Perseus software. Phosphopeptides and
phosphorylation sites signiﬁcantly regulated between the different TLK2 constructs
were determined using Student’s t-test by comparing intensities for the speciﬁc
constructs and results of the analysis were visualized by volcano plots.
HADDOCK docking targeting the ATP-binding pocket. HADDOCK version
2.254 using CNS74 for structure calculations was used to dock the three selected ligands
(CGP74541A, GSK3 inhibitor XIII and the indirubin derivative E804) in the ATP-
binding pocket of the TLK2 kinase domain. The crystal structure of the TLK2 kinase
domain in complex with ATPγS was used to extract the initial coordinates of the
protein for the docking and to identify the residues deﬁning the ATP-binding pocket.
Kinase domain residues with atoms with centres within 10 Å of the centre of any atom
of ATPγS and with all-atom relative solvent accessibility greater than 20% deﬁne the
ATP-binding pocket. This comprises the protein residues H466-K478 (from β1,
β2 strands and the glycine-rich P-loop), Y487-Q494 (β3 strand), Y507, H510, A511
and E514 (αC helix), V527-Y530 (β4 strand), L544-D551, D553 and F554 (β5 strand,
αD helix), D592, K594-L599 and V601 (catalytic loop), K610, T612, D613, G615 and
L616 (magnesium binding loop). The ligand coordinates for the docking were extracted
from the crystal structures of the following complexes: human P21-activated kinase 4 in
complex with CGP74541A (PDB entry 2cdz), human calmodulin-dependent protein
kinase 1D in complex with GSK3 inhibitor XIII (PDB entry 2jc6) and human calcium
calmodulin-dependent protein kinase type II alpha (CAMK2A) in complex with
indirubin E804 (PDB entry 2vz6). The default version topology and parameter ﬁles
provided for proteins in HADDOCK 2.2 were used for generation of the protein and
ligand structures. Histidine residues were protonated per the default setting in HAD-
DOCK; 1000 docked complex structures were generated in the ﬁrst rigid-body docking
step (it0), 200 structures in the semi-ﬂexible simulated annealing (it1) and 200 struc-
tures evaluated in the ﬁnal analysis. Two set of distance restraints were used at different
stages of the docking protocol. For the rigid body docking, it0, the entire binding
pocket and the ligand were deﬁned as active. For the ﬂexible reﬁnement steps, the
binding pocket was deﬁned as passive while the ligand was deﬁned as active. Molecular
dynamics simulations were switched off (the number of MD steps was set to 0) for both
rigid-body high-temperature docking and the slow cooling annealing step of the semi-
ﬂexible simulated annealing. HADDOCK score was used to rank the models. Models
were clustered using the RMSD criteria with a 2.0 Å cut-off. The structures of the top
clusters with lowest HADDOCK scores were examined manually in Pymol.
Data availability. Structure factors and coordinates have been deposited at the
PDB (PDB code 5O0Y). The MS raw data and associated tables have been
deposited in the ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identiﬁers PXD007675 and PXD009095. Other data are available
from the corresponding author upon reasonable request.
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